7 Hepatology Headlines You Missed in November 2025

November brought a series of impactful developments in hepatology, underscoring both therapeutic momentum and ongoing challenges across liver disease. The American Association for the Study of Liver Diseases (AASLD) opened the month with updated practice guidance on semaglutide for metabolic dysfunction-associated steatohepatitis (MASH), marking the first major revision since the organization’s 2023 NAFLD guidance and reflecting rapid evolution in MASLD/MASH care. New investigational data also signaled a shift in long-held assumptions about cirrhosis, with early findings from the phase 2 WAYFIND trial exploring combination therapy with semaglutide, cilofexor, and firsocostat in patients with compensated MASH cirrhosis.